Founders: Tim Durso, MD and Reid Waldman, MD
Location: Waltham, MA
VeraDermics is developing a platform for delivering immunotherapy for pediatric warts. Immunotherapy “works better than the standard of care,” noted cofounder Reid Waldman MD during BIOMEDigital, but “the problems with these injections is that they can be exquisitely painful.”
The company is working to put such immunotherapy into a dissolvable microneedle patch called WartPatch, utilizing an FDA-approved generic active ingredient known to work for warts. The patch would not need to be applied to all warts in a given body region, as the therapy offers a “search and destroy” capability, he said.
WartPatch would be a prescription product for use at home. The company has created an initial prototype and aims for a trial-ready prototype by August 2021.